Delivering future health solutions.
Health & Life Sciences
#1 Biomanufacturing cluster in Europe
1st Life Sciences University Technical College in UK
#1 Research institution in the world for Tropical Medicine
One of largest concentrations of Cat 3 laboratories in the UK
There is no better validation of Liverpool City Region’s medical credentials than the global players that choose to locate and reinvest here. From stem cell and gene therapy treatments and nutraceuticals research and development, to large scale manufacturing and the production of pharmaceuticals, vaccines and biologics.
Liverpool City region is home to companies delivering world-class solutions in life sciences from research and trials to medical manufacturing, including AstraZeneca; Allergan; Baxter Healthcare, Bristol Myers Squibb; Lilly; Nestlé Health Science; Seqirus and Unilever. Significant new investments in modern production facilities at these companies have created a vibrant, efficient and cost-competitive environment to produce new drugs and vaccines.
The emergence of sensor technologies, big data and robotics is changing the possibilities and processes in the life sciences sector. Liverpool City Region is leading the way with its LCR 4.0 programme, creating a new infrastructure that connects physical and digital assets to make the industrial internet a reality. The Hartree Centre at Sci-Tech Daresbury is shaping the future of digital UK pharmaceutical design, development and manufacturing through big data analytics expertise.
Get in touch
- +44(0)151 237 3918
Latest Health & Life Sciences news
CASE STUDY: KNOWLEDGE QUARTER
An innovative place where world-leading academic research meets the very latest clinical technologies. Knowledge Quarter Liverpool (KQ Liverpool) is home to the University of Liverpool, Liverpool John Moores University, Liverpool School of Tropical Medicine and the Royal Liverpool University Hospital and is fast becoming one of the world’s leading innovation districts. Upon completion of its […]
CASE STUDY: SEQIRUS
The world’s no.2 influenza vaccine provider Seqirus, the world’s no.2 influenza vaccine provider, recently announced a £22.1 million investment for its site in Liverpool. The company, which is part of global biotherapeutics leader CSL Limited, is developing a new £15.3 million manufacturing facility to support the production of influenza vaccines at its Liverpool site, complemented […]
Liverpool City Region’s Lab venture secures £100,000 for 100% vegan-friendly testing
A Liverpool city region laboratory has secured £100,000 from Unilever and AstraZeneca to develop vegan-friendly testing for new cosmetics and personal care products.
Liverpool earmarks £21.5m for Paddington Village office
Contractor Morgan Sindall is due to start work on the 10-storey building later this year as it nears completion of the 160,000 sq ft Spine – the first office at Paddington Village, part of the Knowledge Quarter Liverpool development, due to house the Royal College of Physicians.
Covid testing firm BioGrad Diagnostics to create 150 jobs in major investment drive with push into London
A Liverpool -headquartered coronavirus testing firm has invested a seven-figure sum in a move that will see its operations expand with the opening of three new clinics in London and the creation of 150 new jobs.
University of Liverpool spin out enables IBS diagnosis method
Liverpool City Region’s Nidor Diagnostics is working with its industrial partner to carry out final validation of a new diagnostic for irritable bowel syndrome (IBS) before commercial launch.
“There’s nowhere else in the UK and very few places in the world that are better placed than Liverpool to lead on building global pandemic resilience…”
Follow-up feature to Liverpool’s London Real Estate Forum 2021 event. Liverpool post-pandemic – Empowering northern cities by building future resilience and playing to our strengths.